Searched for
NOVARTIS SANDOZ
Novartis to spin off generics biz sandozThe company started a strategic review of Sandoz last October - examining a range of options, including retaining the business, spinning it...- Swiss drugmaker Novartis to spin off generics unit SandozThe Basel-based company, which makes a vast array of drugs including cancer treatment Gleevec and Diovan for hypertension, says it wants to...
- Novartis opens new manufacturing plant in Mumbai to make generic cancer drugsSpread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently h...
- Novartis to slash up to 8,000 jobs globallyNovartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating ...
- COVID-19: Novartis to begin HCQ trialsEven as there is still question hanging over the efficacy of hydroxychloroquine (HCQ) as medication for Covid-19, Swiss drug maker Novartis...
- Novartis scraps sale of assets including COVID-19 hopeful to India's AurobindoNovartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...
- Aurobindo’s buyout of Sandoz assets delayed on FTC queryOn Wednesday, shares of Aurobindo closed 4.8 per cent lower at Rs 450.75 on the BSE.
- Novartis India appoints Milan Paleja as vice chairman and MDPaleja is currently country president at Novartis in India and is also responsible for the pharmaceuticals business in the country. He is a...
- Biocon teams up with Swiss drugmaker Sandoz for next gen biosimilarUnder the terms of the agreement, both companies will share responsibility for end to end development, manufacturing and global regulatory ...
- Biocon teams up with Sandoz for next-gen BiosimilarsBiosimilars are identical copies of highly complex biologic drugs that are said to have the same efficacy.
- Taken remedial actions at two plants in Maharashtra: Drug firm NovartisOn October 22, 2015, the USFDA had issued a warning letter to the company's Sandoz Division concerning Indian sites in Kalwe and Turbhe.
- Novartis gets USFDA warning letter for two plants in IndiaSandoz, the generic drug arm of Swiss drug major Novartis, has received a warning letter from the US health regulator for violations of cur...
- Sandoz gets US FDA warning letter for Turbhe, Kalwe sitesThe observations in the warning letter dated October 22 are related to deficiencies in current good manufacturing practice (cGMP) for finis...
- Sandoz gets warning letter for Turbhe, Kalwe siteSandoz, the generic drug arm of Swiss giant Novartis, has received a warning letter from the US FDA on October 22 for its two Indian sites ...
- Cipla gains as partner Sandoz gets USFDA approval for generic drugCipla surged over 4% in trade after its partner Sandoz received a USFDA nod to launch a generic version of Pulmicort respules.
- Sandoz Inc recalls India-made anti-allergic tablets in USDrug firm Sandoz Inc is recalling India-made 1,023,430 units of anti-allergic Cetirizine HCl chewable tablets in the US due to impurity con...
- Competition Commission of India clears Novartis-GlaxoSmithKline pharma dealThe multi-layered deal involves UK-based GlaxoSmithKline acquiring Novartis's vaccine biz, while latter would purchase GSK's cancer drugs p...
- Retailers end boycott of NovartisOver 7,000 retailers and stockists had stopped selling all the 198 medicines of two firms from April 1, protesting the drugmakers’ practice...
- Novartis, retailers lock horns over direct salesAn open battle has erupted between drug retailers in Mumbai and Novartis, a Swiss company, and its subsidiary Sandoz.
- Novartis posts 7% rise in Q1 net profitPharmaceuticals maker Novartis AG reported a 7 percent rise in first-quarter net income on Monday on the back of a declining dollar and sol...
Load More
